WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsStevanato Group SpA (STVN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 2297% more annual revenue ($28.43B vs $1.19B). STVN leads profitability with a 11.8% profit margin vs 4.1%. STVN trades at a lower P/E of 24.3x. MDLN earns a higher WallStSmart Score of 52/100 (C-).

MDLN

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 8.3Quality: 7.8
Piotroski: 4/9

STVN

Buy

51

out of 100

Grade: C-

Growth: 4.7Profit: 6.5Value: 4.7Quality: 6.3
Piotroski: 4/9Altman Z: 2.39
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDLNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$66.92

Current Price

$42.03

$24.89 discount

UndervaluedFair: $66.92Overvalued
STVNSignificantly Overvalued (-262.8%)

Margin of Safety

-262.8%

Fair Value

$4.30

Current Price

$14.18

$9.88 premium

UndervaluedFair: $4.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN0 strengths · Avg: 0/10

No standout strengths identified

STVN2 strengths · Avg: 8.0/10
Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.9%8/10

Strong operational efficiency at 20.9%

Areas to Watch

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
29.9x4/10

Moderate valuation

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

STVN3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

EPS GrowthGrowth
0.3%4/10

0.3% earnings growth

PEG RatioValuation
3.572/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

Revenue growth of 14.8% demonstrates continued momentum.

Bull Case : STVN

The strongest argument for STVN centers on Price/Book, Operating Margin.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Bear Case : STVN

The primary concerns for STVN are Revenue Growth, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

MDLN is growing revenue faster at 14.8% — sustainability is the question.

STVN generates stronger free cash flow (5M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 51/100) and 14.8% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Stevanato Group SpA

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in integrated solutions tailored for the pharmaceutical and biotechnology sectors. The company excels in the design and manufacturing of glass and polymer packaging for injectable medications, improving efficiency and reliability in the drug delivery process. With a strong commitment to quality and sustainability, Stevanato is well-positioned to benefit from the growing biopharmaceutical market, making it an attractive prospect for institutional investors looking to invest in healthcare innovation and technology advancement.

Want to dig deeper into these stocks?